Optimizing Drug Dosing for the Treatment of Chronic Lymphocytic Leukemia

H&O What drugs are available to treat chronic lymphocytic leukemia? NJ The treatment paradigm for chronic lymphocytic leukemia (CLL) has changed substantially in the past […]

Inotuzumab Ozogamicin, a Nonchemotherapy Option for Relapsed Acute Lymphoblastic Leukemia

H&O What percentage of patients with ALL will develop relapsed disease, and what is their prognosis? HK Among adult and elderly patients with acute lymphoblastic […]

Does FCR Have the Potential to Cure a Subgroup of Patients With Chronic Lymphocytic Leukemia?

H&O When is first-line treatment initiated in patients with CLL? WW In chronic lymphocytic leukemia (CLL), patients should meet a standard criteria to initiate treatment. […]

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

Abstract: Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in […]

When Can Tyrosine Kinase Inhibitors Be Discontinued in Patients With Chronic Myeloid Leukemia?

H&O What are the treatment goals for patients with chronic myeloid leukemia? FM With the use of tyrosine kinase inhibitors (TKIs), life expectancy in chronic […]

Tisagenlecleucel in Pediatric Patients With Acute Lymphoblastic Leukemia

H&O What is tisagenlecleucel? SM Tisagenlecleucel (Kymriah, Novartis) is an engineered T-cell therapy that uses a chimeric antigen receptor (CAR) to redirect the cytotoxic machinery […]

Refining the Management of Polycythemia Vera

H&O What are the clinical characteristics of polycythemia vera? RM Patients with polycythemia vera classically present with erythrocytosis, and they can also have thrombocytosis and/or […]

Recent Insights Into Large Granular Lymphocytic Leukemia

H&O How does LGLL manifest? LN Large granular lymphocytic leukemia (LGLL) is an uncommon lymphoproliferation of mature cytotoxic T cells or natural killer (NK) cells. […]

A Closer Look at Blinatumomab

On March 29, 2018, blinatumomab (Blincyto, Amgen) received an accelerated expanded approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic […]

Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia With IDH2 Mutations: Optimizing the Patient Experience

H&O What is the mechanism of action of enasidenib? GR Enasidenib (Idhifa, Celgene/Agios) is an oral, small molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) […]

Enasidenib for Patients With Relapsed Acute Myeloid Leukemia and the IDH2 Mutation

H&O Which patients with AML are at higher risk for relapse? CD Unfortunately, most adult patients with acute myeloid leukemia (AML) will relapse. Features associated […]

Update on Signal Inhibitors in Chronic Lymphocytic Leukemia

Abstract: The last decade has seen major progress in our understanding of the pathobiology of chronic lymphocytic leukemia (CLL) and the identification of potential new […]

Update on Hairy Cell Leukemia

Abstract: Hairy cell leukemia (HCL) is a chronic B-cell malignancy with multiple treatment options, including several that are investigational. Patients present with pancytopenia and splenomegaly, […]

Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia in Adults: Current Treatments and Future Perspectives

Abstract: Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) accounts for approximately one-fourth of cases of adult ALL. It typically presents with an aggressive clinical course, […]

Advances in CAR T-Cell Therapy for Chronic Lymphocytic Leukemia

H&O How does CAR T-cell therapy work? DP A patient’s T cells are removed through leukapheresis and then genetically modified in the laboratory so that […]

Management of Acute Lymphoblastic Leukemia in Young Adults

Abstract: Substantial interest in acute lymphoblastic leukemia (ALL) in young adults (YAs) and investigations focused on this patient population have resulted in therapeutic advancements that […]

A Mind Map for Managing Minimal Residual Disease in Acute Myeloid Leukemia

Abstract: Advances in detecting traces of leukemia that were previously unidentifiable have increasingly led to the incorporation of information about residual disease into clinical decision […]

Emerging Treatments in Acute Myeloid Leukemia: Current Standards and Unmet Challenges

Abstract: Acute myeloid leukemia (AML) is rare and difficult to treat. Although remission is achieved in most patients with newly diagnosed disease, relapse occurs in […]

Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia: Progress in a New Cancer Subtype

Abstract: Philadelphia chromosome–like (Ph-like) acute lymphoblastic leukemia (ALL) is a newly described, high-risk subtype of B-cell ALL. It is characterized by a gene expression profile […]

Identifying Patients With Leukemia Who Are at Risk for Fungal Infections

H&O Approximately how many patients with leukemia will develop fungal infections? VB The risk of fungal infection varies according to several factors, such as the […]